Theratechnologies Provides Update on Trogarzo (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status

Pharmaceutical Investing

Theratechnologies (TSX:TH) today disclosed, during its annual meeting, information on the number of scripts and reimbursement coverage for Trogarzo™ in the United States. As quoted in the press release: “We are quite pleased with the reaction from patients, physicians and payers since we announced the commercial availability of Trogarzo™ on April 30, 2018,” said Luc …

Theratechnologies (TSX:TH) today disclosed, during its annual meeting, information on the number of scripts and reimbursement coverage for Trogarzo™ in the United States.

As quoted in the press release:

“We are quite pleased with the reaction from patients, physicians and payers since we announced the commercial availability of Trogarzo™ on April 30, 2018,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc. “It did not take long to observe strong interest from HIV clinics and to obtain reimbursement from public and private payers,” added Mr. Tanguay.
“Major private insurers such as Cigna, Aetna, United Healthcare and Kaiser Permanente have already amended their reimbursement policy to include Trogarzo™. As we stand, about 25% of privately insured lives in the U.S. now have access to Trogarzo™. In addition, Medicare has quickly made it possible to approve individual requests. Medicaid coverage has been secured in California and Florida, among others, which, together, represent close to 20% of patients covered under Medicaid state plans. All this happened just two months after approval,” said Mr. Tanguay.

Click here to read the full press release.

Pharmaceutical Investing